Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pafase in severe sepsis
NCT00037687Phase 3Terminated
- Sponsor
- ICOS Corporation
- Start
- Apr 2001
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing rPAF-AH with Placebo (2 arms). Primary endpoint: 28 Day All Cause Mortality. Started Apr 2001; status: terminated.
02
Drugs
recombinant platelet-activating factor acetylhydrolase
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00037687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037687.